GSK Investigational Site
Tranent, West Lothian, EH33 2NE, United Kingdom
NCT Number: NCT00520663
The purpose of this study is to define the absorption, breakdown and excretion of a single dose of radiolabelled SB-649868 and its breakdown products by measuring their concentration in blood, urine and faeces over a 7-10 day period. "Radiolabelled" means that the test drug has a radioactive component to help us track the drug. The safety and tolerability of the test drug will also be assessed.
Looking for future studies?
Notify Me30 year–55 year
Male
Interventional
Phase 1
Tranent, West Lothian, EH33 2NE, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
LH, FSH and testosterone hormones must be within normal reference range.
Exclusion criteria
SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
Time frame: over 7-10 days.
Time frame: over 4 days
Time frame: over the course of the study
GlaxoSmithKline
Industry
An Open-label Study to Determine the Excretion, Balance and Pharmacokinetics of SB649868 After a Single Oral Administration of 14C-SB649868 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07277101
Autism Spectrum Disorder, Autistic Disorder
Shanghai, China
View Trial DetailsNCT04598672
Chronic Disease, Disease Attributes
Oslo, Norway
View Trial DetailsNCT04560595
Anxiety, Anxiety Disorders
Baltimore, Maryland, United States
View Trial DetailsNCT05611099
Dyssomnias, Insomnia, Secondary
Encinitas, California, United States
View Trial Details